Pfizer beats EPS estimates for the 12th quarter. Explore PFE's oncology success, cost-cutting impact, and why it's rated a ...

With that in mind, let's consider two high-yield dividend stocks worth investing in: Pfizer (NYSE: PFE) and Medical ...

Pfizer will pay China’s 3SBio $1.25 billion up front to access a cancer drug that could rival Akeso and Summit’s closely ...

Pfizer has appointed a chief digital officer because of the growing importance of digital technology in R&D and business process, as part of a boardroom shake-up. Last week Pfizer announced that ...

Pfizer could soon launch a multi-billion dollar bid for immunotherapy rivals Bristol-Myers Squibb. But moves into new fields of innovation and digital tech – such as Roche’s buyout of Flatiron ...

Pharmaceutical Product Sales: - Moderate decline in Q1, attributed to Pfizer profit share softness and Latin America ... is doing very well in terms of performance. So we had the best turnaround time.

This positive movement reflects investor optimism about the company’s financial turnaround and future growth prospects. The stock’s performance is noteworthy, given the broader market trends ...

This increase may reflect investor optimism about the company’s future prospects and strategic initiatives, as well as confidence in its cash position and production growth. Looking ahead ...

Covid vaccines developed by Pfizer-BioNTech and Moderna ... “I do not believe there is any prospect for the end to the war this year,” Mick Ryan, a retired Australian general and fellow ...